Revisiting asthma control: How should it best be defined?

Pulmonary Pharmacology and Therapeutics

Volumn 20, Issue 5, 2007, Pages 483-492

  Hanania, Nicola A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Asthma control; Control assessment; IgE; Persistent asthma; Severity; Symptoms

Indexed keywords

ACETYLSALICYLIC ACID; BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; FLUTICASONE; GOLD; METHOTREXATE; MONTELUKAST; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; SALBUTAMOL; SALMETEROL; STEROID;

ARTICLE; ASTHMA; CLINICAL TRIAL; DAILY LIFE ACTIVITY; DISEASE CLASSIFICATION; DISEASE SEVERITY; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTI-ASTHMATIC AGENTS; ASTHMA; FORCED EXPIRATORY VOLUME; HUMANS; PEAK EXPIRATORY FLOW RATE; PRACTICE GUIDELINES AS TOPIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 34447516903     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2006.04.005     Document Type: Article

References (77)

1. American Lung Association: Epidemiology & Statistics Unit. Trends in asthma morbidity and mortality. http://www.lungusa.org/atf/cf/%7B7A8D42C2-FCCA-4604-8ADE-7F5D5E762256%7D/ASTHMA1.PDF. Accessed March 28, 2006.
2. Barnes P.J., Jonsson B., and Klim J.B. The costs of asthma. Eur Respir J 9 (1996) 636-642
3. Smith D.H., Malone D.C., Lawson K.A., Okamoto L.J., Battista C., and Saunders W.B. A national estimate of the economic costs of asthma. Am J Respir Crit Care Med 156 (1997) 787-793
4. Vollmer W.M., Markson L.E., O'Connor E., Frazier E.A., Berger M., and Buist A.S. Association of asthma control with health care utilization: a prospective evaluation. Am J Respir Crit Care Med 165 (2002) 195-199
5. National Asthma Education and Prevention Program. Expert panel report 2: guidelines for the diagnosis and management of asthma (1997), National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD NIH publication 97-4051
6. Global Initiative for Asthma. Global strategy for asthma management and prevention (2004), National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD NIH publication 02-3659
7. Asthma in America: a landmark survey. Executive summary. 1998. www.asthmainamerica.com/aaa_index.html. Accessed March 28, 2006.
8. National Asthma Education and Prevention Program. Expert panel report 2: guidelines for the diagnosis and management of asthma: update on selected topics 2002 (2003), National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD NIH publication 02-5047
9. Juniper E.F., Wisniewski M.E., Cox F.M., Emmett A.H., Nielsen K.E., and O'Byrne P.M. Relationship between quality of life and clinical status in asthma: a factor analysis. Eur Respir J 23 (2004) 287-291
10. Carranza Rosenzweig J.R., Edwards L., Lincourt W., Dorinsky P., and ZuWallack R.L. The relationship between health-related quality of life, lung function and daily symptoms in patients with persistent asthma. Respir Med 98 (2004) 1157-1165
11. Boulet L.P., Phillips R., O'Byrne P., and Becker A. Evaluation of asthma control by physicians and patients: comparison with current guidelines. Can Respir J 9 (2002) 417-423
12. Rabe K.F., Vermeire P.A., Soriano J.B., and Maier W.C. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J 16 (2000) 802-807
13. Wolfenden L.L., Diette G.B., Krishnan J.A., Skinner E.A., Steinwachs D.M., and Wu A.W. Lower physician estimate of underlying asthma severity leads to undertreatment. Arch Intern Med 163 (2003) 231-236
14. Zhang J., Yu C., Holgate S.T., and Reiss T.F. Variability and lack of predictive ability of asthma end-points in clinical trials. Eur Respir J 20 (2002) 1102-1109
15. Demoly P., Crestani B., Leroyer C., Magnan A., Mounedji N., and Humbert M. Control and exacerbation of asthma: a survey of more than 3000 French physicians. Allergy 59 (2004) 920-926
16. Bateman E.D., Boushey H.A., Bousquet J., Busse W.W., Clark T.J., Pauwels R.A., et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study. Am J Respir Crit Care Med 170 (2004) 836-844
17. Braganza S., Sharif I., and Ozuah P.O. Documenting asthma severity: do we get it right?. J Asthma 40 (2003) 661-665
18. Miller M., Johnson C., Miller D., Deniz Y., Bleecker E.R., and Wenzel S.E. Severity assessment in asthma: an evolving concept. J Allergy Clin Immunol 116 (2005) 990-995
19. Dolan C.M., Fraher K.E., Bleecker E.R., Borish L., Chipps B., Hayden M.L., et al. Design and baseline characteristics of the epidemiology and natural history of asthma: outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol 92 (2004) 32-39
20. Heaney L.G., and Robinson D.S. Severe asthma treatment: need for characterizing patients. Lancet 365 (2005) 974-976
21. Pierce R. Spirometry: an essential clinical measurement. Aust Fam Physician 34 (2005) 535-539
22. Bacharier L.B., Strunk R.C., Mauger D., White D., Lemanske Jr. R.F., and Sorkness C.A. Classifying asthma severity in children: mismatch between symptoms, medication use, and lung function. Am J Respir Crit Care Med 170 (2004) 426-432
23. Teeter J.G., and Bleecker E.R. Relationship between airway obstruction and respiratory symptoms in adult asthmatics. Chest 113 (1998) 272-277
24. Gibson P.G., Powell H., and Ducharme F. Long-acting beta2-agonists as an inhaled corticosteroid-sparing agent for chronic asthma in adults and children. Cochrane Database Syst Rev 4 (2005) CD005076
25. Asthma Therapy Assessment Questionnaire (ATAQ). In. West Point. Pensylvania: Merck & Co Inc; 1997-1999.
26. Juniper E.F., O'Byrne P.M., Guyatt G.H., Ferrie P.J., and King D.R. Development and validation of a questionnaire to measure asthma control. Eur Respir J 14 (1999) 902-907
27. Nathan R.A., Sorkness C.A., Kosinski M., Schatz M., Li J.T., Marcus P., et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol 113 1 (2004) 59-65
28. Juniper E.F., Guyatt G.H., Ferrie P.J., and Griffith L.E. Measuring quality of life in asthma. Am Rev Respir Dis 147 (1993) 832-838
29. Barley E.A., Quirk F.H., and Jones P.W. Asthma health status measurement in clinical practice: validity of a new short and simple instrument. Respir Med 92 (1998) 1207-1214
30. Hyland M.E., Ley A., Fisher D.W., and Woodward V. Measurement of psychological distress in asthma and asthma management programmes. Br J Clin Psychol 34 Pt 4 (1995) 601-611
31. Marks G.B., Dunn S.M., and Woolcock A.J. An evaluation of an asthma quality of life questionnaire as a measure of change in adults with asthma. J Clin Epidemiol 46 (1993) 1103-1111
32. Pont L.G., van der Molen T., Denig P., van der Werf G.T., and Haaijer-Ruskamp F.M. Relationship between guideline treatment and health-related quality of life in asthma. Eur Respir J 23 (2004) 718-722
33. Juniper E.F., Bousquet J., Abetz L., Bateman E.D., and for the GOAL committee. Identifying 'well-controlled' and 'not well-controlled' asthma using the Asthma Control Questionnaire. Respir Med 100 4 (2006) 616-621
34. Schatz M., Mosen D., Apter A.J., Zeiger R.S., Vollmer W.M., Stibolt T.B., et al. Relationships among quality of life, severity, and control measures in asthma: an evaluation using factor analysis. J Allergy Clin Immunol 115 (2005) 1049-1055
35. Currie G.P., Jackson C.M., and Lipworth B.J. Does bronchial hyperresponsiveness in asthma matter?. J Asthma 41 (2004) 247-258
36. Shelhamer J.H., Levine S.J., Wu T., Jacoby D.B., Kaliner M.A., and Rennard S.I. NIH conference. Airway inflammation. Ann Intern Med 123 (1995) 288-304
37. Sont J.K., Willems L.N., Bel E.H., van Krieken J.H., Vandenbroucke J.P., and Sterk P.J. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. Am J Respir Crit Care Med 159 (1999) 1043-1051
38. American Thoracic Society. Guidelines for methacholine and exercise challenge testing-1999. Am J Respir Crit Care Med 161 (2000) 309-329
39. Kharitonov S.A., and Barnes P.J. Exhaled markers of pulmonary disease. Am J Respir Crit Care Med 163 (2001) 1693-1722
40. Dupont L.J., Demedts M.G., and Verleden G.M. Prospective evaluation of the validity of exhaled nitric oxide for the diagnosis of asthma. Chest 123 (2003) 751-756
41. Jatakanon A., Lim S., Kharitonov S.A., Chung K.F., and Barnes P.J. Correlation between exhaled nitric oxide, sputum eosinophils, and methacholine responsiveness in patients with mild asthma. Thorax 53 (1998) 91-95
42. Jones S.L., Kittelson J., Cowan J.O., Flannery E.M., Hancox R.J., McLachlan C.R., et al. The predictive value of exhaled nitric oxide measurements in assessing changes in asthma control. Am J Respir Crit Care Med 164 (2001) 738-743
43. Kharitonov S.A., Donnelly L.E., Montuschi P., Corradi M., Collins J.V., and Barnes P.J. Dose-dependent onset and cessation of action of inhaled budesonide on exhaled nitric oxide and symptoms in mild asthma. Thorax 57 (2002) 889-896
44. Smith A.D., Cowan J.O., Brassett K.P., Herbison G.P., and Taylor D.R. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 352 (2005) 2163-2173
45. Vlachos-Mayer H., Leigh R., Sharon R.F., Hussack P., and Hargreave F.E. Success and safety of sputum induction in the clinical setting. Eur Respir J 16 (2000) 997-1000
46. Jatakanon A., Lim S., and Barnes P.J. Changes in sputum eosinophils predict loss of asthma control. Am J Respir Crit Care Med 161 (2000) 64-72
47. Green R.H., Brightling C.E., McKenna S., Hargadon B., Parker D., Bradding P., et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 360 (2002) 1715-1721
48. Little S.A., Chalmers G.W., MacLeod K.J., McSharry C., and Thomson N.C. Non-invasive markers of airway inflammation as predictors of oral steroid responsiveness in asthma. Thorax 55 (2000) 232-234
49. Parameswaran K., and Hargreave F.E. The use of sputum cell counts to evaluate asthma medications. Br J Clin Pharmacol 52 (2001) 121-128
50. Carlton B.G., Lucas D.O., Ellis E.F., Conboy-Ellis K., Shoheiber O., and Stempel D.A. The status of asthma control and asthma prescribing practices in the United States: results of a large prospective asthma control survey of primary care practices. J Asthma 42 (2005) 529-535
51. American Thoracic Society. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. Am J Respir Crit Care Med 162 (2000) 2341-2351
52. Chinn S., Jarvis D., Luczynska C.M., Ackerman-Liebrich U., Anto J.M., Cerveri I., et al. An increase in bronchial responsiveness is associated with continuing or restarting smoking. Am J Respir Crit Care Med 172 (2005) 956-961
53. Tomlinson J.E., McMahon A.D., Chaudhuri R., Thompson J.M., Wood S.F., and Thomson N.C. Efficacy of low and high dose inhaled corticosteroid in smokers versus non-smokers with mild asthma. Thorax 60 (2005) 282-287
54. Wilson N.M. Virus infections, wheeze and asthma. Paediatr Respir Rev 4 (2003) 184-192
55. Harding S.M. Gastroesophageal reflux: a potential asthma trigger. Immunol Allergy Clin North Am 25 (2005) 131-148
56. Yang T.T., Li S., Wyka B., and Kenyon D. Drug delivery performance of the mometasone furoate dry powder inhaler. J Aerosol Med 14 (2001) 487-494
57. Karpel J.P. An easy-to-use dry-powder inhaler. Adv Ther 17 (2000) 282-286
58. Bender B.G., and Bender S.E. Patient-identified barriers to asthma treatment adherence: responses to interviews, focus groups, and questionnaires. Immunol Allergy Clin North Am 25 (2005) 107-130
59. Custovic A., Murray C., and Simpson A. Allergy and infection: understanding their relationship. Allergy 60 Suppl. 79 (2005) 10-13
60. Silverman R.A., Boudreaux E.D., Woodruff P.G., Clark S., and Camargo Jr. C.A. Cigarette smoking among asthmatic adults presenting to 64 emergency departments. Chest 123 (2003) 1472-1479
61. Morgan W.J., Crain E.F., Gruchalla R.S., O'Connor G.T., Kattan M., Evans III R., et al., for the Inner City Asthma Study Group. Results of a home-based environmental intervention among urban children with asthma. N Engl J Med 351 (2004) 1068-1080
62. Ito K., Chung K.F., and Adcock I.M. Update on glucocorticoid action and resistance. J Allergy Clin Immunol 117 3 (2006) 522-543
63. Szefler S.J., Martin R.J., King T.S., Boushey H.A., Cherniack R.M., Chinchilli V.M., et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol 109 (2002) 410-418
64. Tantisira K.G., Lake S., Silverman E.S., Palmer L.J., Lazarus R., Silverman E.K., et al. Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum Mol Genet 13 (2004) 1353-1359
65. Holt S., Suder A., Weatherall M., Cheng S., Shirtcliffe P., and Beasley R. Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis. Br Med J 323 (2001) 253-256
66. Masoli M., Holt S., Weatherall M., and Beasley R. Dose-response relationship of inhaled budesonide in adult asthma: a meta-analysis. Eur Respir J 23 (2004) 552-558
67. Masoli M., Holt S., Weatherall M., and Beasley R. The dose-response relationship of inhaled corticosteroids in asthma. Curr Allergy Asthma Rep 4 (2004) 144-148
68. Lipworth B.J. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med 159 (1999) 941-955
69. Allen D.B., Bielory L., Derendorf H., Dluhy R., Colice G.L., and Szefler S.J. Inhaled corticosteroids: past lessons and future issues. J Allergy Clin Immunol 112 3 Suppl. (2003) S1-S40
70. Mortimer K.J., Harrison T.W., and Tattersfield A.E. Effects of inhaled corticosteroids on bone. Ann Allergy Asthma Immunol 94 (2005) 15-21 quiz 22-3, 79
71. Niven A.S., and Argyros G. Alternate treatments in asthma. Chest 123 (2003) 1254-1265
72. Oettgen H.C., and Geha R.S. IgE regulation and roles in asthma pathogenesis. J Allergy Clin Immunol 107 (2001) 429-440
73. Storms W.W. Unmet needs in the treatment of allergic asthma: potential role of novel biologic therapies. J Manag Care Pharm 9 (2003) 534-543
74. Soler M., Matz J., Townley R., Buhl R., O'Brien J., Fox H., et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 18 (2001) 254-261
75. Buhl R., Hanf G., Soler M., Bensch G., Wolfe J., Everhard F., et al. The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. Eur Respir J 20 (2002) 1088-1094
76. Buhl R., Soler M., Matz J., Townley R., O'Brien J., Noga O., et al. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Eur Respir J 20 (2002) 73-78
77. Lemanske Jr. R.F., Nayak A., McAlary M., Everhard F., Fowler-Taylor A., and Gupta N. Omalizumab improves asthma-related quality of life in children with allergic asthma. Pediatrics 110 (2002) e55